16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]
25 MG/ML · Injection · injection
A form of bevacizumab-tnjn →
16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi] — VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors. Strength, form, class, interactions & more.
![16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3976cf9-9edb-4ca2-9375-9bcd2e32f5b4&name=100+mg+carton.jpg)
Active ingredient
Classification
VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsVascular Endothelial Growth Factor Inhibitor
Drug interactions
Bevacizumab does not have a clinically meaningful effect on the pharmacokinetics of certain drugs, but there may be reduced exposure to paclitaxel when used in combination with carboplatin.
- moderatepaclitaxel — lower paclitaxel exposure after four cycles of treatment
- moderatecarboplatin — lower paclitaxel exposure after four cycles of treatment
- unknownirinotecan — no clinically meaningful effect on pharmacokinetics
- unknowninterferon alfa — no clinically meaningful effect on pharmacokinetics
- unknowncarboplatin — no clinically meaningful effect on pharmacokinetics
- unknownpaclitaxel — no clinically meaningful effect on pharmacokinetics
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication